HZT-501 is under investigation by Horizon Therapeutics, Inc., a privately held biopharmaceutical company. It has entered Phase 3 clinical trials in March 2007 for reduction of the risk of development... HZT-501 is a combination product including ibuprofen and the acid reducing agent famotidine.
- Mechanism
- Curator reviewed
HZT-501 is a proprietary formulation of ibuprofen, the most prescribed NSAID in the United States, combined with famotidine, the most potent H2 receptor antagonist, in a single pill. HZT-501 is specifically designed to provide pain relief while reducing stomach acidity during the peak time of risk for gastric ulceration.
- Primary indication
- Investigated for use/treatment in pain (acute or chronic).Curator reviewed
- Code names
- HZT-501
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with HZT-501, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account